FORM 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 

July 21, 2003

(Date of earliest event reported)

 

IMMUCELL CORPORATION

(Exact name of registrant as specified in its charter)

 

0-15507

(Commission file number)

 

DELAWARE   01-0382980

(State or other jurisdiction of incorporation)

   (I.R.S. Employer Identification No.)

 

56 Evergreen Drive

Portland, ME 04103

(Address of principal executive offices and zip code)

 

(207) 878-2770

(Registrant’s telephone number, including area code)

 

Item 7.    Financial Statements and Exhibits

 

(a)    Not applicable

 

(b)    Not applicable

 

(c)    Exhibits

 

99.1    Press release of Company dated July 21, 2003

 

Item 9.    Regulation FD Disclosure (Information furnished pursuant to Item 12, “Results of Operations and Financial Condition”).

 

On July 21, 2003, ImmuCell Corporation (the “Company”) issued a press release announcing earnings results for the three and six month periods ended June 30, 2003. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

In accordance with the procedural guidance in SEC Release No. 33-8216, the information in this Form 8-K and the Exhibit attached hereto is being furnished under “Item 9. Regulation FD Disclosure” rather than under “Item 12. Results of Operations and Financial Condition.” The information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

       

IMMUCELL CORPORATION

Date: July 22, 2003      

/s/    MICHAEL F. BRIGHAM

       

Michael F. Brigham

President and Chief Executive Officer

EXHIBIT INDEX

 

Exhibit No.
   

Description of Exhibit

99.1

    Press release of the Company dated July 21, 2003